BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E, Kimura T. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell Int 2015;15:117. [PMID: 26675567 DOI: 10.1186/s12935-015-0267-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Wong OGW, Li J, Cheung ANY. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. Front Oncol 2021;11:666815. [PMID: 34737943 DOI: 10.3389/fonc.2021.666815] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Matsuzaki S, Nagase Y, Ueda Y, Kakuda M, Maeda M, Matsuzaki S, Kamiura S. Placenta Previa Complicated with Endometriosis: Contemporary Clinical Management, Molecular Mechanisms, and Future Research Opportunities. Biomedicines 2021;9:1536. [PMID: 34829767 DOI: 10.3390/biomedicines9111536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang J, Yang ZM, Huang Y, Wang KN, Xie Y, Yang N. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis. Kaohsiung J Med Sci 2021;37:940-50. [PMID: 34414664 DOI: 10.1002/kjm2.12420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin YC, Wen KC, Sung PL, Chou YT, Liew PL, Chen LY, Huang RL, Lai HC, Chang LT. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res 2020;13:143. [PMID: 33292376 DOI: 10.1186/s13048-020-00751-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu J, Wang H, Zheng M, Deng L, Zhang X, Lin B. p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma. Int J Mol Med 2020;46:2102-14. [PMID: 33125094 DOI: 10.3892/ijmm.2020.4757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Huang H, Yang L, Tung H, Ku F, Wu R, Tang Y, Chang W, Jung S, Wang C, Lin C, Liu F, Lin G, Chen M, Chou H, Chang T, Chao A, Lai C. Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma. Journal of the Formosan Medical Association 2020;119:793-804. [DOI: 10.1016/j.jfma.2019.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Smalley T, Metcalf R, Patel R, Islam SMA, Bommareddy RR, Acevedo-Duncan M. The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on Invasion Through Decreases in PKC-ζ Protein Expression. Front Oncol 2020;10:209. [PMID: 32175276 DOI: 10.3389/fonc.2020.00209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kakuda M, Matsuzaki S, Ueda Y, Shiomi M, Matsuzaki S, Kimura T, Fujita M, Egawa-Takata T, Kobayashi E, Serada S, Yoshino K, Naka T, Kimura T. Copper ions are novel therapeutic agents for uterine leiomyosarcoma. Am J Obstet Gynecol 2020;222:64.e1-64.e16. [PMID: 31351063 DOI: 10.1016/j.ajog.2019.07.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, Huang RY. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine 2019;50:203-10. [PMID: 31761620 DOI: 10.1016/j.ebiom.2019.11.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
10 Perez-Juarez CE, Arechavaleta-Velasco F, Zeferino-Toquero M, Alvarez-Arellano L, Estrada-Moscoso I, Diaz-Cueto L. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors. Med Oncol 2019;37:4. [PMID: 31713081 DOI: 10.1007/s12032-019-1326-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
11 Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecol Oncol 2019;153:304-11. [PMID: 30792002 DOI: 10.1016/j.ygyno.2019.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Xu M, Jin T, Chen L, Zhang X, Zhu G, Wang Q, Lin Z. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. Gene 2019;696:63-71. [PMID: 30776464 DOI: 10.1016/j.gene.2019.02.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
13 Kobayashi H, Kawahara N, Ogawa K, Yamada Y, Iwai K, Niiro E, Morioka S. Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary. Biomed Rep 2018;9:112-8. [PMID: 30013776 DOI: 10.3892/br.2018.1114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Serhan K, Gartung A, Panigrahy D. Drawing a link between the thromboxane A2 pathway and the role of platelets and tumor cells in ovarian cancer. Prostaglandins Other Lipid Mediat 2018;137:40-5. [PMID: 29933028 DOI: 10.1016/j.prostaglandins.2018.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ueno M, Shiomi T, Mochizuki S, Chijiiwa M, Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, Okada Y. ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death. Cancer Sci 2018;109:471-82. [PMID: 29247567 DOI: 10.1111/cas.13469] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
16 Liu X, Xu Y, Jin Q, Wang W, Zhang S, Wang X, Zhang Y, Xu X, Huang J. EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget 2016;7:20801-9. [PMID: 26989075 DOI: 10.18632/oncotarget.8018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
17 Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. Int J Cancer 2017;141:1856-66. [PMID: 28646535 DOI: 10.1002/ijc.30847] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
18 Lakshminarasimhan R, Andreu-Vieyra C, Lawrenson K, Duymich CE, Gayther SA, Liang G, Jones PA. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. Cancer Lett 2017;401:11-9. [PMID: 28483516 DOI: 10.1016/j.canlet.2017.04.040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
19 Wu X, Ruan Y, Jiang H, Xu C. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. The International Journal of Biochemistry & Cell Biology 2017;85:66-74. [DOI: 10.1016/j.biocel.2017.01.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
20 Li X, Yu Z, Fang L, Liu F, Jiang K. Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients. Med Sci Monit 2017;23:1514-21. [PMID: 28356549 DOI: 10.12659/msm.899990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
21 Mandilaras V, Karakasis K, Clarke B, Oza A, Lheureux S. Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. Expert Opinion on Orphan Drugs 2016;5:71-83. [DOI: 10.1080/21678707.2017.1264300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Chang C, Chiou S, Yang M, Yen M, Wang P. Gene set-based integrative analysis of ovarian clear cell carcinoma. Taiwanese Journal of Obstetrics and Gynecology 2016;55:552-7. [DOI: 10.1016/j.tjog.2016.06.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]